| Drug Name | larotrectinib sulfate |
|---|---|
| Other Drug Names | LOXO-101; larotrectinib; larotrectinib sulfate; oncogenic activating mutation-targeting compound (cancer), Array BioPharma/ Loxo Oncology; tyrosine kinase inhibitor (oral, cancer), Array BioPharma/Loxo Oncology |
| Chemical Name | (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide sulfate (1:1) |
| Formula | C21H22F2N6O2·H2O4S |
| Mol. Wt. | 526.5 |
| CAS No. | 1223405-08-0 |
| UNII | RDF76R62ID |
| Target-based Actions | Trk tyrosine kinase receptor inhibitor |
| Highest Status | Phase 2 Clinical |
| Originator Company | Array BioPharma Inc |
| Structure |
 |
Extended Information